Johnson & Johnson’s (JNJ) MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to treat atrial fibrillation (AFib) in the United States, as it investigates four reported cases of neurovascular events. The pause on Varipulse procedures began on Jan. 5. The FDA had approved the Varipulse platform in November last year.The cases were related to an external rollout plan conducted by J&J. Since the beginning of the external rollout till Jan. 3, J&J completed more than 1 ...